BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26632460)

  • 1. [A multicenter comparison study on the detection of BCR-ABL tyrosine kinase domain point mutation].
    Qin Y; Wang D; Qiao C; Shen H; Geng S; Cao Z; Huang X
    Zhonghua Xue Ye Xue Za Zhi; 2015 Nov; 36(11):902-5. PubMed ID: 26632460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Mascarenhas CC; Cunha AF; Miranda EC; Zulli R; Silveira RA; Costa FF; Pagnano KB; De Souza CA
    Leuk Lymphoma; 2009 Jul; 50(7):1148-54. PubMed ID: 19557636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A multicenter comparison study on the quantitative detection of bcr-abl (P210) transcript levels in China].
    Qin YZ; Cheng H; Cen JN; Geng SX; Li QH; Li XQ; Lin ZX; Ma DX; Qiao C; Wang YG; Li JL; Li LD; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):104-8. PubMed ID: 23611214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
    Ernst T; Gruber FX; Pelz-Ackermann O; Maier J; Pfirrmann M; Müller MC; Mikkola I; Porkka K; Niederwieser D; Hochhaus A; Lange T
    Haematologica; 2009 Sep; 94(9):1227-35. PubMed ID: 19608684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
    Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
    Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy.
    Hanfstein B; Müller MC; Kreil S; Ernst T; Schenk T; Lorentz C; Schwindel U; Leitner A; Hehlmann R; Hochhaus A
    Haematologica; 2011 Mar; 96(3):360-6. PubMed ID: 21134983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia.
    Ernst T; Hoffmann J; Erben P; Hehlmann R; Hochhaus A; Müller MC
    Clin Chem Lab Med; 2008; 46(3):318-22. PubMed ID: 18303987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
    He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
    Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A multicenter study on the validation of conversion factor for the conversion of BCR-ABL (P210) transcript levels to the international scale in chronic myeloid leukemia].
    Qin Y; Lin Z; Cen J; Li X; Li Q; Cheng H; Geng S; Wang Y; Ma D; Qiao C; Li J; Li L; Huang X
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):134-7. PubMed ID: 24606655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of BCR-ABL mutations and resistance to imatinib mesylate.
    Branford S; Hughes T
    Methods Mol Med; 2006; 125():93-106. PubMed ID: 16502579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Detection of BCR-ABL in Chronic Myeloid Leukemia.
    Qin YZ; Huang XJ
    Methods Mol Biol; 2016; 1465():1-15. PubMed ID: 27581134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the «BCR/ABL - multitest» kit in the algorithm of laboratory diagnostics of oncohematological diseases: economic aspects.
    Gorbenko AS; Stolyar MA; Vasiliev EV; Mikhalev MA; Bakhtina VI; Olkhovik TI; Mochalova EE; Orlova KE; Olkhovskiy IA
    Klin Lab Diagn; 2021 Sep; 66(9):571-576. PubMed ID: 34543537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.
    Zhang JG; Lin F; Chase A; Goldman JM; Cross NC
    Blood; 1996 Mar; 87(6):2588-93. PubMed ID: 8630427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
    Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
    Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML).
    Arana-Trejo RM; Ruíz Sánchez E; Ignacio-Ibarra G; Báez de la Fuente E; Garces O; Gómez Morales E; Castro Granados M; Ovilla Martínez R; Rubio-Borja ME; Solís Anaya L; Herrera P; Delgado Llamas J; Kofman S
    Clin Lab Haematol; 2002 Jun; 24(3):145-50. PubMed ID: 12067277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
    Etienne G; Dulucq S; Huguet F; Schmitt A; Lascaux A; Hayette S; Fort MP; Sujobert P; Bijou F; Morisset S; Tavitian S; Bidet A; Turcq B; Robbesyn F; Chollet C; Belloc F; Durrieu F; Mahon FX; Nicolini FE
    Cancer Med; 2019 Sep; 8(11):5173-5182. PubMed ID: 31350815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pyrosequencing-based test for detection and relative quantification of the BCR-ABL1 T315I point mutation.
    Schumacher JA; Szankasi P; Bahler DW; Ho AK; Kelley TW
    J Clin Pathol; 2011 Jul; 64(7):618-25. PubMed ID: 21486895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A multicenter study on the revalidation of validated conversion factor for the conversion of BCRABL(P210)transcript levels to the international scale in chronic myeloid leukemia].
    Qin Y; Ma D; Wang Y; Wang L; Wang Y; Liu S; Lu X; Li X; Cen J; Xiao M; Lin Z; Geng S; Liang C; Chen H; Han C; Han W; Huang X
    Zhonghua Xue Ye Xue Za Zhi; 2015 Oct; 36(10):814-7. PubMed ID: 26477757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of ABL tyrosine kinase point mutations in imatinib treated chronic myelogenous leukemia patients].
    Qin YZ; Liu YR; Li JL; Ruan GR; Zhu HH; Jiang Q; Fu JY; Lu Y; Chang Y; Li LD; Huang XJ; Chen SS; Qiu JY
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3186-9. PubMed ID: 16405837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemia.
    Khorashad JS; Thelwell N; Milojkovic D; Marin D; Watson JA; Goldman JM; Apperley JF; Foroni L; Reid AG
    J Clin Pathol; 2008 Jul; 61(7):863-5. PubMed ID: 18587017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.